Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.47 |
| ▸ | BCR | P11274 | 2/20 | 0.47 |
| ▸ | ABL2 | P42684 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.46 |
| ▸ | IKBKB | O14920 | 2/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31339983 | 0.85 | PIK3CA (0.51) | ABL1BCRIKBKBHDAC8 | |
| SCHEMBL31339978 | 0.78 | BTK (0.48) | PTGS1TRPV1SORT1 | |
| SCHEMBL5465537 | 0.75 | KMO (0.61) | ABL1BCRSORT1 | |
| SCHEMBL678064 | 0.75 | PTGS1 (0.77) | PTGS1HDAC8TRPV1 | |
| SCHEMBL5100707 | 0.74 | CAMKK2 (0.49) | HDAC8 | |
| SCHEMBL25336685 | 0.74 | IKBKB (0.63) | ABL1BCRIKBKBDYRK1ACAMK2D | |
| SCHEMBL31119043 | 0.74 | IKBKB (0.63) | ABL1BCRIKBKBDYRK1ACAMK2D | |
| SCHEMBL31396428 | 0.72 | TRPV1 (0.65) | PTGS1TRPV1 | |
| SCHEMBL24174770 | 0.72 | TRPV1 (0.65) | PTGS1TRPV1 | |
| SCHEMBL1259604 | 0.72 | KIF11 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124202-A1 | CD97 AND GSDME INTERACTION INHIBITOR HAVING ANTI-TUMOR ACTIVITY AND APPLICATION THEREOF | JILIN UNIVERSITY (CN) | 2026-05-07 | — | — | US | disclosed |
| EP-4725485-A1 | CD97 AND GSDME INTERACTION INHIBITOR HAVING ANTI-TUMOR ACTIVITY AND APPLICATION THEREOF | Jilin University (CN) | 2026-04-15 | — | — | EP | disclosed |
| CN-119285557-A | CD97 and GSDME interaction inhibitor with anti-tumor activity and application thereof | 吉林大学 | 2025-01-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124202-A1 | CD97 AND GSDME INTERACTION INHIBITOR HAVING ANTI-TUMOR ACTIVITY AND APPLICATION THEREOF | GZMB, CD74, GSDMD | ABL1 2523/4885BCR 1620/4885ABL2 3813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.